ZA955740B - Anti-protozoan methods and materials - Google Patents

Anti-protozoan methods and materials

Info

Publication number
ZA955740B
ZA955740B ZA955740A ZA955740A ZA955740B ZA 955740 B ZA955740 B ZA 955740B ZA 955740 A ZA955740 A ZA 955740A ZA 955740 A ZA955740 A ZA 955740A ZA 955740 B ZA955740 B ZA 955740B
Authority
ZA
South Africa
Prior art keywords
protozoan
methods
materials
bacteriocidal
bpi
Prior art date
Application number
ZA955740A
Other languages
English (en)
Inventor
Lewis H Lambert Jr
Original Assignee
Xoma Corp A Legal Body Organis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp A Legal Body Organis filed Critical Xoma Corp A Legal Body Organis
Publication of ZA955740B publication Critical patent/ZA955740B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/12—Fertilization attaching inhibition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
  • Packages (AREA)
ZA955740A 1994-07-11 1995-07-11 Anti-protozoan methods and materials ZA955740B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/273,470 US5646114A (en) 1994-07-11 1994-07-11 Anti-protozoan methods

Publications (1)

Publication Number Publication Date
ZA955740B true ZA955740B (en) 1997-01-07

Family

ID=23044078

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA955740A ZA955740B (en) 1994-07-11 1995-07-11 Anti-protozoan methods and materials

Country Status (9)

Country Link
US (3) US5646114A (de)
EP (1) EP0769959B1 (de)
JP (1) JPH10502642A (de)
AT (1) ATE240743T1 (de)
AU (1) AU2967595A (de)
CA (1) CA2194895A1 (de)
DE (1) DE69530844D1 (de)
WO (1) WO1996001647A1 (de)
ZA (1) ZA955740B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5646114A (en) 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CN1236320A (zh) * 1996-05-10 1999-11-24 爱克斯欧玛公司 杀菌的/增强通透性的蛋白质产物用于人脑膜炎球菌血症的治疗用途
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
WO1998019694A1 (en) * 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
DE60002552T2 (de) * 1999-01-22 2004-02-26 Xoma Technology Ltd., Berkeley Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
US6875584B1 (en) * 1999-03-02 2005-04-05 University Of Georgia Research Foundation, Inc. Prophylactic and therapeutic immunization against protozoan infection and disease
US6955908B1 (en) * 2000-06-21 2005-10-18 Lambl Barbara B Organism associated with nongonococcal urethritis
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US9212201B2 (en) * 2010-07-23 2015-12-15 Acea Biotech, Inc. Antifungal and antiparasitic polyene macrolides
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5217956A (en) * 1988-10-21 1993-06-08 The Children's Hospital Of Philadelphia Composition and treatment with biologically active peptides and certain anions
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
EP0605653A4 (de) * 1991-09-26 1995-03-15 Incyte Pharma Inc Neue art eines liposaccharid bindendes protein (lbp).
US5234822A (en) * 1991-10-17 1993-08-10 New England Medical Center Hospitals, Inc. Trypanosoma cruzi heparin-binding protein and antibodies thereto
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
ES2132239T3 (es) * 1992-05-19 1999-08-16 Xoma Corp Metodos mejorados para la preparacion de proteinas de union a endotoxinas.
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
DE69410254T2 (de) * 1993-03-12 1998-12-17 Xoma Corp., Berkeley, Calif. Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP0690720B1 (de) * 1993-03-12 2001-06-27 XOMA Technology Ltd. Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials

Also Published As

Publication number Publication date
US6440936B2 (en) 2002-08-27
US20010029245A1 (en) 2001-10-11
EP0769959B1 (de) 2003-05-21
WO1996001647A1 (en) 1996-01-25
CA2194895A1 (en) 1996-01-25
ATE240743T1 (de) 2003-06-15
EP0769959A1 (de) 1997-05-02
AU2967595A (en) 1996-02-09
US6013629A (en) 2000-01-11
DE69530844D1 (de) 2003-06-26
JPH10502642A (ja) 1998-03-10
US5646114A (en) 1997-07-08

Similar Documents

Publication Publication Date Title
ZA955740B (en) Anti-protozoan methods and materials
MX9602570A (es) Metodos y materiales anti-fungosos.
AU3909497A (en) Anti-chlamydial methods and materials
CA2115348A1 (en) Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
WO1994016073A3 (en) Methods and reagents for inhibiting furin endoprotease
BG101118A (en) Therapeutical compounds
EP1421948A3 (de) Verwendung von Botulinum Toxine zur Behandlung vom Schwitzen bei Menschen
AP9801392A0 (en) Concentrated antibody preparation.
BG100974A (en) Vaccines against papillomavirus
EP0776163A4 (de) Bakteriophagen kodierende enzyme zur behandlung und vorbeugung von zahnkaries und periodontalen erkrankungen
IL122386A0 (en) Anti-fungal and anti-bacterial histatin-based peptides
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
WO1997018790A3 (en) Therapeutic and diagnostic agents for the treatment of microbial infections
DE69420145D1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
ZA947783B (en) Method of treating depressed reticuloendothelial system function
MY115014A (en) Mouth-care products
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EP0955366A4 (de) Antigenes protein aus malassezia
NZ335401A (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
TW223019B (de)
BG100055A (en) Kalfinella sacoidosis sp. novo strain for making preparations for allergological, serological and immunological diagnosis of sarcoidosis, crohn's disease and mediterranean fever
GEP19991605B (en) Inhibitor, Its Obtaining and Use
UA8333A1 (uk) Спосіб лікування септичних захворювань
HK1015695A (en) Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury